Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros




Base de datos
Intervalo de año de publicación
1.
World J Urol ; 33(12): 2053-62, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-25981401

RESUMEN

PURPOSE: Interruption of renal blood flow is often necessary during nephron sparing surgery (NSS) and can induce renal injury. This study examines whether tadalafil, a phosphodiesterase-5 (PDE-5) inhibitor and well-known vasodilator, exerts nephroprotective effects in patients undergoing NSS. METHODS: This non-randomized study included 49 patients with enhancing solid renal mass. All patients were subjected to open NSS during which clamping the renal artery was performed. Twenty-two patients were pretreated with tadalafil 1 day prior NSS and 2 days following surgery. The other 27 patients underwent the same surgical procedure but did not receive tadalafil (controls). Urine samples were collected before surgery and following renal pedicle clamp removal. Urine levels of NGAL and KIM-1, two novel biomarkers for acute kidney injury (AKI), were determined. RESULTS: Clamping the renal artery induced kidney dysfunction as reflected by increases in urinary NGAL and KIM-1 in all participants. These increases in urinary NGAL and KIM-1 excretion were evident 1 h after renal ischemia and lasted for 72 and 24 h, respectively. Pretreatment with tadalafil reduced the absolute urinary excretion of KIM-1, but not of NGAL. Although the incidence of AKI was comparable between tadalafil-treated and untreated NSS subjects, the elevation in serum creatinine (SCr) was significantly attenuated in tadalafil-treated group as compared with NSS controls. CONCLUSIONS: Tadalafil exerts nephroprotective effects in AKI following NSS, as was evident by reduced urinary excretion of KIM-1 and attenuation of SCr elevation. Carefully controlled large clinical studies are needed before defining the role of PDE-5 inhibition therapy in these patients.


Asunto(s)
Lesión Renal Aguda/prevención & control , Proteínas de Fase Aguda/metabolismo , Neoplasias Renales/cirugía , Lipocalinas/metabolismo , Glicoproteínas de Membrana/metabolismo , Inhibidores de Fosfodiesterasa 5/uso terapéutico , Proteínas Proto-Oncogénicas/metabolismo , Receptores Virales/metabolismo , Tadalafilo/uso terapéutico , Lesión Renal Aguda/etiología , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores , Carcinoma/patología , Carcinoma/cirugía , Creatinina/sangre , Femenino , Receptor Celular 1 del Virus de la Hepatitis A , Humanos , Isquemia , Neoplasias Renales/patología , Lipocalina 2 , Masculino , Persona de Mediana Edad , Nefrectomía/efectos adversos , Nefronas , Estudios Prospectivos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA